{"title":"肿瘤比例方案一线治疗同时伴有EGFR敏感突变和PD-L1高表达的转移性鳞状细胞肺癌1例报告","authors":"N. X, Xie H, Z. Z, Zou J","doi":"10.16966/2470-0991.265","DOIUrl":null,"url":null,"abstract":"A 56-year-old Asian male with 20 years smoking history was admitted to the hospital due to a cough with sputum production. Chest Computed Tomography (CT) revealed a tumor shadow in the right middle lung, and transbronchial biopsy diagnosed Lung Squamous Cell Carcinoma (LCSS). Further molecular pathological assessment detected Epidermal Growth Factor Receptor (EGFR) sensitive mutation, while Programmed Death-Ligand 1 (PD-L1) was highly expressed with a Tumor Proportion Score (TPS) of >70%. Tumor Proportion (TP) regime was the first-line of treatment gained an obvious reduction in tumor size. Until head progression was found, the patient took Osimertinib orally and is currently stable. Given the rarity of the LCSS with EGFR mutation and high-expressed PD-L1, this case report provides a successful clinical treatment option for doctors in similar situations.","PeriodicalId":115205,"journal":{"name":"Journal of Surgery: Open Access","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumor Proportion Regime First-Line Therapy in Metastatic Squamous Cell Lung Cancer with both EGFR Sensitive Mutation and High PD-L1 Expression: A Case Report\",\"authors\":\"N. X, Xie H, Z. Z, Zou J\",\"doi\":\"10.16966/2470-0991.265\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 56-year-old Asian male with 20 years smoking history was admitted to the hospital due to a cough with sputum production. Chest Computed Tomography (CT) revealed a tumor shadow in the right middle lung, and transbronchial biopsy diagnosed Lung Squamous Cell Carcinoma (LCSS). Further molecular pathological assessment detected Epidermal Growth Factor Receptor (EGFR) sensitive mutation, while Programmed Death-Ligand 1 (PD-L1) was highly expressed with a Tumor Proportion Score (TPS) of >70%. Tumor Proportion (TP) regime was the first-line of treatment gained an obvious reduction in tumor size. Until head progression was found, the patient took Osimertinib orally and is currently stable. Given the rarity of the LCSS with EGFR mutation and high-expressed PD-L1, this case report provides a successful clinical treatment option for doctors in similar situations.\",\"PeriodicalId\":115205,\"journal\":{\"name\":\"Journal of Surgery: Open Access\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Surgery: Open Access\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.16966/2470-0991.265\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgery: Open Access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.16966/2470-0991.265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Tumor Proportion Regime First-Line Therapy in Metastatic Squamous Cell Lung Cancer with both EGFR Sensitive Mutation and High PD-L1 Expression: A Case Report
A 56-year-old Asian male with 20 years smoking history was admitted to the hospital due to a cough with sputum production. Chest Computed Tomography (CT) revealed a tumor shadow in the right middle lung, and transbronchial biopsy diagnosed Lung Squamous Cell Carcinoma (LCSS). Further molecular pathological assessment detected Epidermal Growth Factor Receptor (EGFR) sensitive mutation, while Programmed Death-Ligand 1 (PD-L1) was highly expressed with a Tumor Proportion Score (TPS) of >70%. Tumor Proportion (TP) regime was the first-line of treatment gained an obvious reduction in tumor size. Until head progression was found, the patient took Osimertinib orally and is currently stable. Given the rarity of the LCSS with EGFR mutation and high-expressed PD-L1, this case report provides a successful clinical treatment option for doctors in similar situations.